| Cat.No. | Name | Information |
|---|---|---|
| M3030 | S-Ruxolitinib | S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. |
| M1820 | Tofacitinib | Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM. |
| M1660 | AZ 960 | AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro. |
| M1646 | AG490 | AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). |
| M1733 | TG101348 | TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM. |
| M1787 | INCB18424 | Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo. |
| M5944 | Ruxolitinib phosphate | Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. |
| M3616 | Tofacitinib citrate | Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1. |
| M2346 | Filgotinib | Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively. |
| M2044 | AZD1480 | AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively. |
| M49604 | JAK-IN-24 | JAK-IN-24 is a JAK inhibitor, with IC50s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. |
| M49603 | JAK-IN-21 | JAK-IN-21 is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively. |
| M49602 | JAK-IN-20 | JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. |
| M49601 | JAK-IN-19 | JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC50=7.2 and HLF Eotaxin pIC50=7.7). |
| M49600 | JAK-IN-18 | JAK-IN-18 is a potent inhibitor of JAK. |
| M49599 | JAK-IN-17 | JAK-IN-17 is a potent inhibitor of JAK. |
| M49598 | JAK-IN-15 | JAK-IN-15 is a JAK inhibitor. |
| M49597 | JAK-IN-14 | JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. |
| M49596 | JAK-IN-10 | JAK-IN-10 is a JAK inhibitor. |
| M49595 | JAK3-IN-9 | JAK3-IN-9 is an orally active JAK3 inhibitor with IC50 value of 1.7 nM. |
| M49594 | JAK3-IN-7 | JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM. |
| M49593 | JAK3-IN-12 | JAK3-IN-12 is a highly potent JAK3 inhibitor with IC50 values of 9.5 nM, 18 nM and 42 nM for JAK3, JAK1 and JAK2, respectively. |
| M49592 | JAK3-IN-11 | JAK3-IN-11 , a potent, noncytotoxic, irreversible, orally active JAK3 inhibitor with IC50 value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. |
| M49591 | JAK3/BTK-IN-5 | JAK3/BTK-IN-5 is a potent inhibitor of JAK3/BTK. |
| M49590 | JAK3/BTK-IN-4 | JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. |
| M49589 | JAK3/BTK-IN-3 | JAK3/BTK-IN-3 is a potent inhibitor of JAK3/BTK. |
| M49588 | JAK3/BTK-IN-2 | JAK3/BTK-IN-2 is a potent inhibitor of JAK3/BTK. |
| M49587 | JAK3/BTK-IN-1 | JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. |
| M49586 | JAK3 covalent inhibitor-1 | JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. |
| M49585 | JAK2-IN-7 | JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
